Drug Safety Update: Botulinum toxin type A products: updated warnings regarding risk of iatrogenic botulism

Cases of iatrogenic botulism have been reported following the therapeutic or cosmetic use of botulinum toxin containing products where the toxin’s effect extends beyond the area of treatment. Patients should seek immediate medical advice if they experience any of the signs and symptoms consistent with the spread of toxin or if they experiencedifficulties with swallowing, speech or breathing.

Advice for Patients:

• Treatment with botulinum toxin has in rare cases caused botulism and other serious adverse reactions and symptoms which can occur up to 4 weeks following treatment
• If you experience any symptoms of botulism following treatment with botulinum toxin including difficulty swallowing, slurred speech and breathing difficulty, seek immediate medical attention via emergency services
• Your administering practitioner (who should be appropriately trained and qualified) should verify that the product being used is licensed for use in the UK. Use of
  unlicensed or counterfeit products can significantly increase your risk of adverse reactions. Refer to the NHS advice for information on choosing your administering practitioner. Please refer to the following links for a list of registered independent healthcare providers for England (private hospitals and clinics)
• Report any suspected side effects following botulinum toxin to the Yellow Card scheme